US Merger & Acquisition SEC Filings — July 28, 2026

28-07-2026

Denali Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company for gross proceeds of $195.0 million. The PRV was received upon FDA approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome in March 2026. The sale closed on July 27, 2026, pursuant to an asset purchase agreement dated June 12, 2026.

• · PRV was received from FDA approval of AVLAYAHTM for Hunter syndrome (MPS II) in March 2026.
• · Asset purchase agreement was dated June 12, 2026.
• · The full text of the PRV Transfer Agreement will be filed as an exhibit to a subsequent SEC filing.

28-07-2026

Keen Vision Acquisition Corp. (KVACU) filed a Fifth Amended and Restated Memorandum and Articles of Association on July 28, 2026, adopted by shareholders on July 21, 2026. The filing updates the company's governing documents, including provisions for share redemption, business combination requirements, and director indemnification. No financial results or material agreements were disclosed in this filing.

• · The company is authorized to issue up to 500,000,000 shares of USD 0.0001 each.
• · Public Shares have redemption rights upon Automatic Redemption Event, Tender Redemption Offer, Redemption Offer, or Amendment Redemption Event.
• · Fair Value for a business combination is defined as at least 80% of the Trust Account balance (excluding deferred underwriting fees and taxes).
• · The memorandum includes detailed indemnification provisions for directors and officers.
• · No amendment to the business combination provisions (Regulation 23) is allowed before a business combination unless public shareholders are given redemption rights.

28-07-2026

Knox Lane completed its acquisition of Cross Country Healthcare, taking the company private. Joel Tremblay was appointed CEO, succeeding Kevin C. Clark who retired. The locums division was sold to All Star Healthcare Solutions, a Knox Lane portfolio company.

• · Transaction closed July 21, 2026.
• · Cross Country Healthcare becomes a privately held, standalone company.
• · Kevin C. Clark will support transition.
• · Joel Tremblay previously President of Medical Solutions.
• · BofA Securities provided fairness opinion.
• · Davis Polk & Wardwell LLP legal counsel to Cross Country.
• · MTS Health Partners financial advisor to Knox Lane; Kirkland & Ellis LLP legal counsel to Knox Lane.

28-07-2026

T1 Energy Inc. (TE-WT) announced the acquisition of foundational solar patents and other IP from Evervolt Green Energy Holding Pte Ltd. for $135 million. The deal eliminates future royalty payments and strengthens T1's position as a vertically integrated U.S. solar manufacturer. However, T1 faces significant financing risks, with $133 million payable in four installments through October 2026, and the company has a material weakness in internal controls and needs a comprehensive financing solution for its capital expenditure.

• · The patents were previously licensed by T1 from Evervolt.
• · The acquisition eliminates future royalty payments on the IP.
• · Any issuance of T1 common stock for installments will be at a 15% discount to a five-trading-day VWAP.
• · The company has a material weakness in its internal control over financial reporting and requires comprehensive financing for G2_Austin Phase 1.
• · T1 completed a transformative transaction in December 2024 to position itself as a leading U.S. solar manufacturer.

28-07-2026

Core University Living Real Estate Income Trust completed the acquisition of a four-property student housing portfolio (the 'Seed Portfolio') for $303,500,000 on July 22, 2026. The portfolio, located in Lexington, KY; Morgantown, WV; and Gainesville, FL, was 99.4% pre-leased for the 2026-2027 academic year as of March 31, 2026. The acquisition was funded with a $180,400,400 mortgage loan from JPMorgan Chase and proceeds from share sales, and the loan carries a Term SOFR + 1.50% interest rate with a 4.0% cap.

• · The seller was a joint venture between a third party and an entity owned by several principals of Core Spaces, LLC, the Company's sponsor.
• · The loan matures on July 22, 2029, with two one-year extension options subject to conditions including no default, a debt service coverage ratio test, and a loan-to-value ratio not exceeding 60.0% for the first extension.
• · Partial prepayments must be at least $250,000.
• · The interest rate cap agreement was entered into by Core Morgantown LLC, a borrower under the Loan.

28-07-2026

EchoStar Corporation has established a $2.4B Wireless Creditor Trust as a condition of FCC approval for its spectrum license assignments to AT&T and SpaceX. The trust will hold $2.4B in proceeds from the AT&T transaction to pay eligible tort, breach of contract, and other claims related to EchoStar's network construction and operations. A $200M reserve is segregated for Type A claims, with The Bank of New York Mellon serving as trustee.

• · Trust is named 'Wireless Creditor Trust' and established under FCC Orders DA 26-470 and DA 26-471 dated May 12, 2026.
• · Trust is intended to be exempt from Securities Act of 1933 and Investment Company Act of 1940.
• · Trust will remain subject to the FCC Wireless Telecommunications Bureau's continuing jurisdiction.
• · The $200M Type A Claims Reserve is secured by a security agreement and deposit account control agreement in favor of DISH Wireless L.L.C. as secured party.
• · Claimants may file only one Covered Claim per person/entity.
• · Beneficiaries include: (a) holders of Eligible Type A Claims, (b) holders of Eligible Type B-1/B-2 Claims (after Type A and expenses are paid), and (c) EchoStar for any remainder.

28-07-2026

Southern Cross Acquisition I Corp. completed its IPO of 11,500,000 units at $10.00 per unit on July 22, 2026, generating gross proceeds of $115,000,000, including full exercise of the underwriters' over-allotment option. Concurrently, it sold 239,300 private units to its sponsor for $2,393,000. A total of $115,000,000 from the proceeds was placed in a trust account for public shareholders and underwriters.

• · The IPO included full exercise of underwriters' over-allotment option for 1,500,000 additional units.
• · Each unit consists of one ordinary share ($0.0001 par value), one redeemable warrant (exercise price $11.50 per share), and one right (entitling holder to one-fourth of one ordinary share upon initial business combination).
• · Private units are identical to IPO units, subject to limited exceptions described in the Registration Statement on Form S-1 (File No. 333-296723).
• · Trust account is held with Continental Stock Transfer & Trust Company as trustee.
• · Company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.

28-07-2026

Charlton Aria Acquisition Corp appointed Paul Strickland as CFO and director, Kyoung Tak Kim as independent director and audit committee member, and Wang Jo Cha as independent director and compensation committee member, effective July 22, 2026. Jung Min Lee ceased as acting CFO but remains CEO. The appointments are part of the SPAC's preparation for a business combination, with deferred cash compensation for Strickland payable upon deal closure.

• · Paul Strickland's compensation is deferred and payable in a lump sum upon consummation of a business combination, with no interest accrued.
• · Kyoung Tak Kim is a licensed CPA in New York, New Jersey, Georgia, and South Korea, and a partner at LEK Partners LLC.
• · Wang Jo Cha has four decades of experience in South Korean public finance and capital markets, including senior roles at KRX and KOSCOM.
• · The company is a blank check company (SPAC) with a fiscal year end of December 31.

28-07-2026

Yarrow Bioscience completed its merger with VYNE Therapeutics, with the combined company now operating as Yarrow Bioscience and trading on Nasdaq under the ticker 'YARW'. The merger was supported by approximately $200 million in private financings led by RTW Investments, with participation from OrbiMed, Janus Henderson Investors, and others. Yarrow has initiated dosing in a Phase 2a/2b trial of YB-101 for Graves' disease, with Phase 2a data expected in 2H 2027, and the company expects its cash runway to fund operations into 2028. However, the merger resulted in a significant reverse stock split (1-for-50) for legacy VYNE shares, and the combined company's outstanding common stock is only approximately 2.8 million shares (or 33.6 million fully diluted), reflecting substantial dilution for prior VYNE shareholders.

• · The merger closed on July 27, 2026, with shares trading on Nasdaq under 'YARW' starting July 28, 2026.
• · VYNE distributed a special cash dividend of $17.3 million ($0.40242 per share) on July 23, 2026, prior to the merger.
• · The reverse stock split of VYNE common stock at 1-for-50 was effected on July 24, 2026.
• · The new CUSIP number for the combined company is 92941V407.
• · YB-101 has received FDA Fast Track Designation.
• · Phase 2a data expected in 2H 2027; Phase 2b expected to commence in 1H 2028.
• · Data from the MAD portion of GenSci's Phase 1 TED trial also expected in 2H 2027.
• · Cash runway expected to support operations into 2028.

28-07-2026

Axiom Intelligence Acquisition Corp 1 (SPAC) entered into a promissory note agreement with Axiom Intelligence Holdings 1 LLC for up to $1,000,000 to fund working capital in connection with its initial business combination. The note is non-interest bearing, matures upon the earlier of the business combination or liquidation, and is convertible into units at $10.00 per unit at the payee's option. The payee has waived any claim against the SPAC's trust account.

• · The note is governed by New York law.
• · The payee waives any claim against the trust account established in connection with the IPO.
• · Conversion units are identical to units issued in the private placement at IPO closing.
• · Class A ordinary shares underlying conversion units do not entitle holder to trust account funds or voting on initial business combination.
• · Holders are entitled to up to 3 demand registrations and piggyback registration rights under the existing Registration Rights Agreement dated June 17, 2025.

28-07-2026

Market Technology Acquisition Corp, a newly organized SPAC, announced the pricing of its $200 million initial public offering of 20,000,000 units at $10.00 per unit. The units, consisting of one Class A ordinary share and one-half of one redeemable warrant, are expected to trade on Nasdaq under the ticker "MTAKU" starting July 24, 2026. The company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units to cover over-allotments, and the offering is expected to close on July 27, 2026.

• · The company is a blank check company (SPAC) focused on businesses in the global capital markets ecosystem, particularly licensed U.S. equities and options clearing businesses and related market infrastructure.
• · The registration statement was declared effective by the SEC on July 23, 2026.
• · The offering is being made only by means of a prospectus, copies of which may be obtained from BTIG, LLC.